- Home
- » Tags
- » Iron sucrose
Top View
- 212320Orig1s000
- Anemia in Chronic Kidney Disease: from Pathophysiology and Current Treatments, to Future Agents
- Medical Policy Update Bulletin Medical Policy, Medical Benefit Drug Policy & Coverage Determination Guideline Updates
- PASS Information
- Comparison of Intravenous Iron Sucrose Alone Versus Intravenous
- Anemia: Nutritional Deficiencies
- IV Iron Table
- Evaluation of Intravenous Iron Sucrose Therapy for Iron Deficiency Anaemia in Pregnancy
- Le Fer Dans L'insuffisance Rénale Chronique Terminale
- Anemia, Iron, Erythropoietin
- Treatment of Iron Deficiency in Gastroenterology: a New Paradigm
- Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
- Ferric Maltol (Feraccru®)
- Managing CKD Anemia with 2020 Vision Dan Martinusen Bsc(Pharm), ACPR, Pharmd, FCSHP Outline
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Renal Anaemia
- Triferic® Dialysate and Triferic® AVNU, Develop FPC for New Indications, and Maintain Concentrate Sales
- New Brunswick Drug Plans Formulary
- MONOFERRIC (Ferric Derisomaltose) Injection, for Intravenous Use Serious Hypersensitivity to Monoferric Or Any of Its Components
- Venofer®) Guidelines for Use October 2010
- IV Iron Replacement Therapy for Adults – OUTPATIENT ORDERS
- “Implementation of an Outpatient Iron Infusion Clinic: Alternative Approach to Treat Iron Deficiency Anemia in Pregnancy”
- Feraccru, INN-Ferric Maltol
- Iron Therapy in Chronic Kidney Disease: Days of Future Past
- 203565Orig1s000
- Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
- Intravenous Iron Replacement Therapy “Notification” POLICY EFFECTIVE OCTOBER 1, 2021 Restricted Product(S)
- IV Iron Products
- The Safety of Iron Dextran
- Practice Guidelines in Oncology™ Cancer- and Chemotherapy- Induced Anemia
- Nutrition for Anemia • Javier Diaz-Castro • Javier
- Highmark List of Procedure Codes Requiring NDC Effective 07/01/2021
- Epoetin Alfa (N=1716)
- Oral Iron Therapies in Development for Iron Deficiency in Chronic Kidney Disease
- KDIGO Executive Conclusions
- Monoferric™ (Ferric Derisomaltose)
- Table of Contents Manufacturers
- Public Assessment Report
- Anemia of Inflammation with an Emphasis on Chronic Kidney Disease
- New Brunswick Drug Plans Formulary
- Full Prescribing Information
- Dosing & Administration
- Iron Suppresses Erythropoietin Expression Via Oxidative Stress-Dependent Hypoxia-Inducible Factor-2 Alpha Inactivation
- Safety and Efficacy of Iron Sucrse in Mild to Moderate Anaemia
- Étude Observationnelle De L'usage Clinique Du Fer Injectable Au CHU
- Feissues in Iron Management
- What Is the Effect of Intravenous Iron Supplementation on Exercise Capacity and Quality of Life in Patients with IPAH and Iron Deficiency?